医師の一分

アクセスカウンタ

zoom RSS ホルモン補充療法による卵巣癌のリスク

<<   作成日時 : 2009/07/17 20:00   >>

ブログ気持玉 0 / トラックバック 0 / コメント 0

 閉経後のホルモン補充療法を受けた女性は卵巣癌のリスクが高いと、デンマークからの報告。50-79才女性90万人以上の研究によれば、8年間で140人以上がホルモン療法と関連した卵巣癌を発症し、治療を受けなかった人に比べて38%もリスクが高かった。ホルモン療法は卵巣癌の5%を占めていた。
 政府統計では卵巣癌は米国で毎年女性10万人あたり約18人が診断され、2007年に15,000人が死亡している。
-------------------
長期ホルモン補充療法で約20万人が乳ガン発症/米国医療事情
http://kurie.at.webry.info/200902/article_9.html
乳がんタイプの変化とライフスタイル/英国医療事情
http://kurie.at.webry.info/200902/article_39.html
米国で がん発症率の低下/米国医療事情
http://kurie.at.webry.info/200811/article_53.html
-------------------------------------------------------
Study Cites Hormones as Cancer Risk
http://www.nytimes.com/2009/07/15/health/research/15cancer.html
By REUTERS
Published: July 14, 2009

CHICAGO (Reuters) ― Women who took hormone replacement therapy after menopause had a sharply increased risk of ovarian cancer, researchers in Denmark are reporting.

In a study of more than 900,000 Danish women ages 50 to 79, the scientists found 140 extra cases of ovarian cancer linked to hormone treatment over eight years. That translated to a 38 percent greater risk of contracting the disease, compared with women who did not receive the therapy.

Hormone therapy accounted for 5 percent of the cases of ovarian cancer in the study period, the researchers reported in The Journal of the American Medical Association.

“Even though this share seems low, ovarian cancer remains highly fatal, so accordingly this risk warrants consideration,” wrote the researchers, led by Lina Steinrud Morch of Copenhagen University.

The findings were similar to those in the 2002 Women’s Health Initiative study, which was stopped early because it found an increased risk of ovarian cancer, breast cancer, strokes and other health problems from hormone therapy.

Use of the treatment plunged after those findings were reported, and sales of Prempro, the combined estrogen-progestin therapy sold by Wyeth, have fallen 50 percent since 2001, to around $1 billion a year.

Wyeth’s director of global medical affairs, Dr. Corrado Altomare, who was not involved in the Danish study, said that for women considering hormone therapy, family history and personal medical history “certainly” come into play.

The risks of ovarian cancer were about the same from hormone therapy regardless of the duration of use, the formulation of the hormones, the estrogen dose or how it was administered, according to the study.

As in earlier studies, the recent one found that the cancer risk diminished about two years after therapy was stopped.

Ovarian cancer is diagnosed in roughly 18 out of 100,000 women in the United States each year, according to government statistics, and it killed 15,000 Americans in 2007.
-------------------------------------------------------
Hormone Therapy and Ovarian Cancer

Lina Steinrud M?rch, MSc; Ellen L?kkegaard, MD, PhD; Anne Helms Andreasen, MSc; Susanne Kru"ger-Kj?r, MD, DrMSci; ?jvind Lidegaard, MD, DrMSci

画像JAMA. 2009;302(3):298-305.

Context Studies have suggested an increased risk of ovarian cancer among women taking postmenopausal hormone therapy. Data are sparse on the differential effects of formulations, regimens, and routes of administration.

Objective To assess risk of ovarian cancer in perimenopausal and postmenopausal women receiving different hormone therapies.

Design and Setting Nationwide prospective cohort study including all Danish women aged 50 through 79 years from 1995 through 2005 through individual linkage to Danish national registers. Redeemed prescription data from the National Register of Medicinal Product Statistics provided individually updated exposure information. The National Cancer Register and Pathology Register provided ovarian cancer incidence data. Information on confounding factors and effect modifiers was from other national registers. Poisson regression analyses with 5-year age bands included hormone exposures as time-dependent covariates.

Participants A total of 909 946 women without hormone-sensitive cancer or bilateral oophorectomy.

Main Outcome Measure Ovarian cancer.

Results In an average of 8.0 years of follow-up (7.3 million women-years), 3068 incident ovarian cancers, of which 2681 were epithelial cancers, were detected. Compared with women who never took hormone therapy, current users of hormones had incidence rate ratios for all ovarian cancers of 1.38 (95% confidence interval [CI], 1.26-1.51) and 1.44 (95% CI, 1.30-1.58) for epithelial ovarian cancer. The risk declined with years since last use: 0 to 2 years, 1.22 (95% CI, 1.02-1.46); more than 2 to 4 years, 0.98 (95% CI, 0.75-1.28); more than 4 to 6 years, 0.72 (95% CI, 0.50-1.05), and more than 6 years, 0.63 (95% CI, 0.41-0.96). For current users the risk of ovarian cancer did not differ significantly with different hormone therapies or duration of use. The incidence rates in current and never users of hormones were 0.52 and 0.40 per 1000 years, respectively, ie, an absolute risk increase of 0.12 (95% CI, 0.01-0.17) per 1000 years. This approximates 1 extra ovarian cancer for roughly 8300 women taking hormone therapy each year.

Conclusion Regardless of the duration of use, the formulation, estrogen dose, regimen, progestin type, and route of administration, hormone therapy was associated with an increased risk of ovarian cancer.


Author Affiliations: Gynaecological Clinic, Rigshospitalet, Copenhagen University, Copenhagen (Ms M?rch and Dr Lidegaard); Gynaecological-Obstetrical Department, Hiller?d Hospital, Copenhagen University, Copenhagen (Dr L?kkegaard); Research Center for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark (Mss M?rch and Andreasen), Glostrup; and Department of Virus, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, ?sterbro, Denmark (Dr Kru"ger-Kj?r).

テーマ

関連テーマ 一覧


月別リンク

ブログ気持玉

クリックして気持ちを伝えよう!
ログインしてクリックすれば、自分のブログへのリンクが付きます。
→ログインへ

トラックバック(0件)

タイトル (本文) ブログ名/日時

トラックバック用URL help


自分のブログにトラックバック記事作成(会員用) help

タイトル
本 文

コメント(0件)

内 容 ニックネーム/日時

コメントする help

ニックネーム
本 文
ホルモン補充療法による卵巣癌のリスク 医師の一分/BIGLOBEウェブリブログ
文字サイズ:       閉じる